­

A Probability Approach to Pharmaceutical Demand and Price Setting: Does the Identity of the Third-Party Payer Matters for Prescribing Doctors?

Lenke til artikkel:

[PDF]

Forfattere:

Dalen, Dag Morten, Marilena Locatelli, Enrico Sorisio og Steinar Strøm

År:

2011

Referanse:

Andre skrifter
CES Working paper serie, no 3643

Summary

TNF-alpha inhibitors represent one of the most important areas of biopharmaceuticals by sales, with three blockbusters accounting for 8 per cent of total pharmaceutical sale in Norway. Novelty of the paper is to examine, with the use of a unique natural policy experiment in Norway, to what extent the price responsiveness of prescription choices is affected when the identity of the third-party payer changes. The three dominating drugs in this market, Enbrel, Remicade, and Humira, are substitutes, but have had different and varying funding schemes - hospitals and the national insurance plan. A stochastic structural model for the three drugs, covering demand and price setting, is estimated in a joint maximum likelihood approach. We find that doctors are more responsive when the costs are covered by the hospitals compared to when costs are covered by national insurance.

Nøkkelord:

pharmaceuticals, discrete choice model, funding-schemes

JEL:

C350, D430, I180, L110

Prosjekt info:

Oppdragsgiver: Norges forskningsråd
Oppdragsgivers prosjektnr.:
Frisch prosjekt: 4111 - Government financing of drug consumption in Norway and the markets for pharmaceuticals